Singapore, July 8 -- Catalent and Nanoscope Therapeutics have expanded their partnership to support late-phase clinical development and commercial supply of MCO-010, Nanoscope's lead optogenetic gene therapy.

Under the expanded agreement, Catalent will provide commercial-compliant packaging and distribution for MCO-010. Catalent has also secured the commercial packaging validation programme intended to support Nanoscope's Biologics License Application.

This is relevant because advanced therapy commercialisation depends on more than clinical efficacy. Gene therapies require specialised manufacturing, packaging, distribution and quality systems before they can be delivered reliably at scale. For therapies approaching regulatory submission...